WATERTOWN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of ...
Reports Q2 revenue $0 vs. $1.1M last year. “We continue to advance the differentiated technology born out of our PREDATOR platform and capitalize on the strong foundation of clinical data from our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback